{'fraction_non_alphanumeric': 0.02217741935483871, 'fraction_numerical': 0.010080645161290322, 'mean_word_length': 5.716216216216216, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients

Interleukin (IL)-17A has been shown to represent a key-role cytokine in psoriasis pathogenesis; recently, several studies have summarized the efficacy and safety data of two currently approved biologics inhibiting this inflammatory pathway, namely secukinumab and ixekizumab, both showing high rates of maintained skin clearance and low incidence of adverse events.